AstraZeneca plc : FDA Advisory Committee Recommends the Investigational SGLT2 Inhibitor Dapagliflozin for the Treatment of Type 2 Diabetes in Adults

13-12-2013 4-tradersComments (0)

AstraZenecaBristol-Myers SquibbdapagliflozinDiabetesPharmaceutical

(4-traders.com) AstraZeneca (NYSE:AZN) and Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted 13-1 that the benefits of dapagliflozin use outweigh identified risks and support marketing of...

Read more on 4-traders

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top